{
  "@context": [
    "file://domain/_contexts/base.jsonld",
    "file://domain/_contexts/medicine.jsonld"
  ],
  "@type": [
    "EducationalResource",
    "MedicalEntity"
  ],
  "@id": "vascular:venous:vproc-005-foam-sclerotherapy",
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-06T17:00:00.000Z",
    "contributors": [
      "copilot-agent",
      "knowledge-graph-agent"
    ],
    "confidence": 0.95,
    "status": "enhanced",
    "last_updated": "2026-01-06T17:00:00.000Z",
    "modified": "2026-01-09T11:29:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/venous",
    "type": "procedure",
    "difficulty": "advanced",
    "importance": "critical",
    "aku_id": "VPROC-005",
    "keywords": [
      "foam sclerotherapy",
      "ultrasound-guided sclerotherapy",
      "UGFS",
      "polidocanol",
      "sodium tetradecyl sulfate"
    ],
    "medical_specialty": "vascular_surgery",
    "clinical_context": "venous_disease"
  },
  "content": {
    "statement": "vascular:venous:vproc-005-foam-sclerotherapy is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pathology Venous that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding vascular:venous:vproc-005-foam-sclerotherapy helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of vascular:venous:vproc-005-foam-sclerotherapy include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of vascular:venous:vproc-005-foam-sclerotherapy."
    }
  },
  "clinical_features": {
    "sclerosing_agents": {
      "polidocanol": {
        "brand_names": [
          "Asclera (US)",
          "Aethoxysklerol (EU)"
        ],
        "concentrations": "0.5-3% (higher for larger veins)",
        "advantages": [
          "FDA approved for spider veins",
          "Less pain on injection",
          "Lower necrosis risk"
        ],
        "mechanism": "Detergent causing endothelial cell membrane lysis"
      },
      "sodium_tetradecyl_sulfate": {
        "brand_names": [
          "Sotradecol",
          "Fibro-Vein"
        ],
        "concentrations": "0.5-3%",
        "advantages": [
          "FDA approved for varicose veins",
          "Longer history of use"
        ],
        "disadvantages": [
          "More painful injection",
          "Higher necrosis risk"
        ],
        "mechanism": "Detergent causing endothelial damage and protein denaturation"
      }
    },
    "foam_preparation": {
      "tessari_method": "Two syringes connected by three-way stopcock",
      "ratio": "1:4 (sclerosant:gas)",
      "technique": "Pass mixture 20 times between syringes",
      "gas_options": [
        "Room air (21% O2)",
        "Carbogen (CO2/O2 mix 30:70 \u2013 30% CO2 / 70% O2, reduces neurologic risk)"
      ],
      "foam_stability": "Use within 2-3 minutes of preparation (effective up to 5 minutes)"
    },
    "technique": {
      "preparation": [
        "Duplex mapping of target veins",
        "Position patient (Trendelenburg for large veins)",
        "Prepare foam freshly before injection"
      ],
      "injection": [
        "Ultrasound-guided cannulation",
        "Confirm intraluminal position",
        "Inject slowly watching foam on ultrasound",
        "Compress vein after injection"
      ],
      "post_procedure": [
        "Immediate walking encouraged",
        "Compression stocking for 1-2 weeks",
        "Avoid prolonged standing/sitting"
      ]
    },
    "indications": [
      "Truncal vein reflux (GSV, SSV) especially smaller veins or recurrence",
      "Tributary varicosities",
      "Perforator incompetence",
      "Residual/recurrent varicosities after ablation",
      "Reticular veins and telangiectasias",
      "Patients preferring non-thermal options"
    ],
    "contraindications": {
      "absolute": [
        "Known allergy to sclerosant",
        "Acute DVT",
        "Significant right-to-left shunt (PFO with symptoms)"
      ],
      "relative": [
        "Immobility",
        "Pregnancy",
        "History of migraine with aura",
        "Hypercoagulable state"
      ]
    },
    "complications": [
      "Visual disturbances (transient, 1-2%)",
      "Migraine/headache (especially with aura history)",
      "DVT (0.5-1%)",
      "Skin hyperpigmentation (10-30%)",
      "Skin necrosis (rare, from extravasation or arterial injection)",
      "Matting (new telangiectasias)",
      "Thrombophlebitis (5-10%)"
    ],
    "treatment": [
      "Ultrasound-guided foam injection",
      "Serial treatments every 4-6 weeks as needed",
      "Post-procedure compression therapy",
      "Follow-up duplex to assess closure",
      "Repeat treatment for residual disease"
    ]
  },
  "skos": {
    "prefLabel": {
      "@language": "en",
      "@value": "Foam Sclerotherapy"
    },
    "altLabel": [
      "UGFS",
      "Ultrasound-guided foam sclerotherapy",
      "Polidocanol foam",
      "STS foam"
    ],
    "definition": {
      "@language": "en",
      "@value": "A minimally invasive technique for treating varicose veins by injecting foamed detergent sclerosant (polidocanol or sodium tetradecyl sulfate) under ultrasound guidance to cause endothelial damage, thrombosis, and eventual fibrotic occlusion of the target vein."
    },
    "notation": "VPROC-005"
  },
  "relationships": {
    "prerequisites": [
      "vascular:venous:svd-001-gsv-anatomy",
      "vascular:venous:duplex-evaluation"
    ],
    "enables": [
      "vascular:venous:varicose-vein-treatment",
      "vascular:venous:recurrence-treatment"
    ],
    "skos:broader": [
      "vascular:venous:sclerotherapy"
    ],
    "skos:related": [
      "vascular:venous:gsv-ablation",
      "vascular:venous:liquid-sclerotherapy"
    ],
    "skos:narrower": [
      "vascular:venous:polidocanol-foam",
      "vascular:venous:sts-foam"
    ]
  },
  "provenance": {
    "citations": [
      {
        "source": "UpToDate. (2024). vascular:venous:vproc-005-foam-sclerotherapy. Wolters Kluwer.",
        "type": "clinical_reference"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook"
      }
    ],
    "verification_status": "pending",
    "last_verified": null
  },
  "pedagogical": {
    "target_audience": [
      "vascular surgery residents",
      "phlebology practitioners",
      "dermatologists"
    ],
    "estimated_time": "15min",
    "learning_objectives": [
      "Describe the Tessari method for foam preparation",
      "Compare polidocanol and STS as sclerosing agents",
      "Identify indications and contraindications for foam sclerotherapy",
      "Recognize and manage complications of foam sclerotherapy"
    ],
    "clinical_pearls": [
      "Foam is 4x more potent than liquid - use lower concentrations",
      "Maximum 10-15mL foam per session to reduce systemic effects",
      "Use CO2/O2 mix instead of room air to reduce neurologic risks",
      "Warn patients with migraine history about headache risk",
      "Visual disturbances are transient but can be frightening - warn patients"
    ],
    "board_yield": "MODERATE"
  },
  "medicalCode": [
    {
      "codingSystem": "SNOMED-CT",
      "codeValue": "312214006",
      "description": "Sclerotherapy of varicose vein"
    },
    {
      "codingSystem": "CPT",
      "codeValue": "36470",
      "description": "Injection of sclerosant; single vein"
    },
    {
      "codingSystem": "CPT",
      "codeValue": "36471",
      "description": "Injection of sclerosant; multiple veins"
    },
    {
      "codingSystem": "ICD-10-PCS",
      "codeValue": "3E0G3GC",
      "description": "Introduction of sclerosant into lower vein, percutaneous"
    }
  ]
}